Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Chloroquine AND (Coronavirus 2019 OR COVID-19 OR SARS-CoV-2))
1,829 results
  • Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. [Review]
    Cochrane Database Syst Rev. 2021 02 12; 2:CD013587.Singh B, Ryan H, … Fletcher T
  • CONCLUSIONS: HCQ for people infected with COVID-19 has little or no effect on the risk of death and probably no effect on progression to mechanical ventilation. Adverse events are tripled compared to placebo, but very few serious adverse events were found. No further trials of hydroxychloroquine or chloroquine for treatment should be carried out. These results make it less likely that the drug is effective in protecting people from infection, although this is not excluded entirely. It is probably sensible to complete trials examining prevention of infection, and ensure these are carried out to a high standard to provide unambiguous results.
  • QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. [Journal Article]
    Eur J Prev Cardiol. 2020 Nov 22 [Online ahead of print]Ahmadizar F, Soroush N, … Stricker BH
  • CONCLUSIONS: In this longitudinal study, persons who received [hydroxy]chloroquine had an increased QTc-interval duration and the association was dose-dependent. [Hydroxy]chloroquine was associated with a significantly increased risk of SCD. As long as their activity against COVID-19 is controversial, cardiotoxicity is a strong argument against using these drugs to treat COVID-19 infections.
  • Psychiatric side effects of chloroquine in COVID-19 patients: two case reports. [Case Reports]
    Pan Afr Med J. 2020; 35(Suppl 2):83.Benjelloun R, Otheman Y, El Kettani C
  • Chloroquine and hydroxy chloroquine are widely use in Africa and all over the world as anti-malarial drugs but also in the treatment of chronic inflammatory diseases. Since the outbreak of COVID-19 pandemic, Morocco have included this medication in the COVID-19 treatment guidelines in association with azithromycine. Besides dermatologic problems, ocular impairments and gastro-intestinal effects, …
  • Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review. [Journal Article]
    Mol Biol Rep. 2021 Feb 23 [Online ahead of print]Onori ME, Ricciardi Tenore C, … Minucci A
  • The coronavirus disease 2019 (COVID-19) is until today a global health emergency. In an immense effort, effective drugs against COVID-19 are searched and intensive researches on possible repurposing of antiviral agents are performed. Since chloroquine (CQ) and hydroxychloroquine (HCQ) have shown in vitro anti- COVID-19 activities, the potential effect of CQ/HCQ to treat and/or prevent COVID-19 in…
  • Tetracycline as an inhibitor to the SARS-CoV-2. [Journal Article]
    J Cell Biochem. 2021 Feb 22 [Online ahead of print]Zhao TY, Patankar NA
  • The coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains an extant threat against public health on a global scale. Cell infection begins when the spike protein of SARS-CoV-2 binds with the human cell receptor, angiotensin-converting enzyme 2 (ACE2). Here, we address the role of tetracycline as an inhibitor for the receptor-binding domain (RBD) of the spike protein. Tar…
  • Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: Review and Appraisal of Current Evidence. [Review]
    J Natl Black Nurses Assoc. 2020 Dec; 31(2):1-14.Powell-Young YM, Alzaghari O, … Giger JN
  • Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated coronavirus disease 19 (COVID-19) began ravaging most of the globe in November 2019. In the United States more than 25 million people have been infected with SARS-CoV-2. To date, COVID-19 has killed close to 400,000 U.S. citizens. In the face of limited pharmacotherapies, the current burden of SARS-CoV-2 and COVID-1…
  • Therapeutic Strategies in the Management of COVID-19. [Review]
    Front Mol Biosci. 2020; 7:636738.Naik RR, Shakya AK
  • Since December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 are trying to content the virus by isolating the patients and treating them with the approved antivir…
  • Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. [Journal Article]
    Sens Actuators B Chem. 2021 May 01; 334:129663.Suh JS, Kim HS, Kim TJ
  • The global outbreak of coronavirus disease and rapid spread of the causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent a significant threat to human health. A key mechanism of human SARS-CoV-2 infection is initiated by the combination of human angiotensin-converting enzyme 2 (hACE2) and the receptor-binding domain (RBD) of the SARS-CoV-2-derived spike glycoprotein. De…
  • Multidrug treatment for COVID-19. [Journal Article]
    Drug Discov Ther. 2021 Feb 19 [Online ahead of print]Ohe M, Furuya K, Goudarzi H
  • An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which began in Wuhan, China in December 2019, has rapidly spread all over the world. The World Health Organization characterized the disease caused by SARS-CoV-2 (COVID-19) as a pandemic in March 2020. In the absence of specific treatments for the virus, treatment options are being examined. Drug repurposing is…
  • Synthetic and medicinal perspective of quinolines as antiviral agents. [Review]
    Eur J Med Chem. 2021 Jan 24; 215:113220.Kaur R, Kumar K
  • In current scenario, various heterocycles have come up exhibiting crucial role in various medicinal agents which are valuable for mankind. Out of diverse range of heterocycle, quinoline scaffold have been proved to play an important role in broad range of biological activities. Several drug molecules bearing a quinoline molecule with useful anticancer, antibacterial activities etc have been marke…
  • Medical progress: Stem cells as a new therapeutic strategy for COVID-19. [Review]
    Stem Cell Res. 2021 Feb 11; 52:102239.Musial C, Gorska-Ponikowska M
  • Currently, the world is facing the SARS-CoV-2 pandemic, coronavirus of acute respiratory distress syndrome 2, causes of COVID-19. Coronaviruses are RNA single-stranded viruses that have an envelope. In addition, coronaviruses are classified into four subfamilies: alpha, beta, gamma and delta coronaviruses. The first of them, cause mildly symptomatic or asymptomatic infections, while beta-coronavi…
  • Effect of Chloroquine and Hydroxychloroquine on COVID-19 Virological Outcomes: An Updated Meta-Analysis. [Review]
    Indian J Med Microbiol. 2020 Jul-Dec; 38(3-4):265-272.Das RR, Behera B, … Naik SS
  • As anti-malarial drugs have been found to inhibit Corona viruses in vitro, studies have evaluated the effect of these drugs inCOVID-19 infection. We conducted an updated meta-analysis of clinical trials and observational studies published till June 2020. Patients with reverse transcription polymerase chain reaction (RT-PCR) confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) infe…
  • Small-molecule antiviral agents in ongoing clinical trials for COVID-19. [Journal Article]
    Curr Drug Targets. 2021 Feb 14 [Online ahead of print]Apaydın ÇB, Çınar G, Cihan-Üstündağ G
  • The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019 and has rapidly spread globally. As the confirmed number of cases has reached to 83 million worldwide, the potential severity and the deadly complications of the disease requires urgent development of effective drugs for prevention and treatment…
  • An update review of emerging small-molecule therapeutic options for COVID-19. [Review]
    Biomed Pharmacother. 2021 Feb 03; 137:111313.Tian D, Liu Y, … Cao W
  • The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a challenge to global health. At present, many candidate small-molecule therapeutics have been developed that can inhibit both the infection and replication of SARS-CoV-2 and even potentially relieve cytokine storms and other related complications. Meanwhile, host-targeted drugs that inhibit cellular transmembrane seri…
New Search Next